^
CANCER:
Gastrointestinal Cancer
FGFR2 rearrangement
|
Cholangiocarcinoma
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
pemigatinib Sensitive: A1 - Approval
Innovent Biologics Press Release - 3 days
|
pemigatinib Sensitive: A1 - Approval
Innovent Biologics Press Release - 3 days
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
pemigatinib Sensitive: A1 - Approval
Innovent Biologics Press Release - 3 days
|
pemigatinib Sensitive: A1 - Approval
Innovent Biologics Press Release - 3 days
|
PD-L1 expression
|
Gastric Cancer
|
PD-L1 expression
|
Gastric Cancer
|
tislelizumab Sensitive: B - Late Trials
BeiGene Press Release - 4 days
|
tislelizumab Sensitive: B - Late Trials
BeiGene Press Release - 4 days
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
tislelizumab Sensitive: B - Late Trials
BeiGene Press Release - 4 days
|
tislelizumab Sensitive: B - Late Trials
BeiGene Press Release - 4 days
|
PD-L1 overexpression
|
Gastric Cancer
|
PD-L1 overexpression
|
Gastric Cancer
|
pembrolizumab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
pembrolizumab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
PD-L1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
pembrolizumab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
CYNK-101 Sensitive: B - Late Trials
Celularity Press Release - 1 week
|
CYNK-101 Sensitive: B - Late Trials
Celularity Press Release - 1 week
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
CYNK-101 Sensitive: B - Late Trials
Celularity Press Release - 1 week
|
CYNK-101 Sensitive: B - Late Trials
Celularity Press Release - 1 week
|
GPX4 rs4807542
|
CRC
|
GPX4 rs4807542
|
CRC
|
cetuximab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
cetuximab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
TXN2 rs4821494
|
CRC
|
TXN2 rs4821494
|
CRC
|
cetuximab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
cetuximab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
PD-L1 overexpression
|
Esophageal Adenocarcinoma
|
PD-L1 overexpression
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
nivolumab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
PD-L1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
nivolumab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
PD-L1 overexpression
|
Gastric Cancer
|
PD-L1 overexpression
|
Gastric Cancer
|
nivolumab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
nivolumab Sensitive: B - Late Trials
ASCO-GI 2022 - 1 week
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
nivolumab + trastuzumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
nivolumab + trastuzumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
PD-L1 expression
|
Rectal Cancer
|
PD-L1 expression
|
Rectal Cancer
|
nivolumab Sensitive: C3 – Early Trials
Clin Cancer Res - 1 week
|
nivolumab Sensitive: C3 – Early Trials
Clin Cancer Res - 1 week
|
FGFR1 fusion
|
Cholangiocarcinoma
|
FGFR1 fusion
|
Cholangiocarcinoma
|
erdafitinib Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
erdafitinib Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
PD-L1 overexpression + TMB-H
|
Anal Carcinoma
|
PD-L1 overexpression + TMB-H
|
Anal Carcinoma
|
EGFR inhibitor + Immunotherapy Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
EGFR inhibitor + Immunotherapy Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
KRAS mutation
|
CRC
|
KRAS mutation
|
CRC
|
bevacizumab + PCM-075 Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
bevacizumab + PCM-075 Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
KRAS mutation
|
CRC
|
KRAS mutation
|
CRC
|
pembrolizumab + selinexor Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
pembrolizumab + selinexor Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab + ramucirumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
trastuzumab + ramucirumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
MSI-H/dMMR
|
Gastrointestinal Cancer
|
MSI-H/dMMR
|
Gastrointestinal Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
Immunotherapy Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
DKK1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
DKK1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
tislelizumab + DKN-01 Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
tislelizumab + DKN-01 Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
HRAS mutation
|
CRC
|
HRAS mutation
|
CRC
|
pembrolizumab + selinexor Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
pembrolizumab + selinexor Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
NRAS mutation
|
CRC
|
NRAS mutation
|
CRC
|
pembrolizumab + selinexor Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
pembrolizumab + selinexor Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
GAST expression
|
Gastric Cancer
|
GAST expression
|
Gastric Cancer
|
PAS Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
PAS Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
CCKBR expression
|
Gastric Cancer
|
CCKBR expression
|
Gastric Cancer
|
PAS Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
PAS Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
PD-L1 expression
|
Gastric Cancer
|
PD-L1 expression
|
Gastric Cancer
|
PAS Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
PAS Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
HLA-A*02
|
Gastric Cancer
|
HLA-A*02
|
Gastric Cancer
|
GSK2636771 Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
GSK2636771 Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
PIK3R1 M326I
|
Gastric Cancer
|
PIK3R1 M326I
|
Gastric Cancer
|
GSK2636771 Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
GSK2636771 Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
EGFR inhibitor Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
EGFR inhibitor Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
tislelizumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
tislelizumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
ATM mutation
|
Gastrointestinal Cancer
|
ATM mutation
|
Gastrointestinal Cancer
|
rucaparib Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
rucaparib Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
TMB-L
|
CRC
|
TMB-L
|
CRC
|
bevacizumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
bevacizumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab + camrelizumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
trastuzumab + camrelizumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
trastuzumab + camrelizumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
trastuzumab + camrelizumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
KRAS G12C
|
Pancreatic Ductal Adenocarcinoma
|
MRTX849 Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
MRTX849 Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
TNFRSF9 elevation
|
HCC
|
TNFRSF9 elevation
|
HCC
|
sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
nivolumab Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
trifluridine/tipiracil Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
trifluridine/tipiracil Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
trifluridine/tipiracil Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
trifluridine/tipiracil Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
nivolumab + trastuzumab + gimeracil/oteracil/tegafur Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
nivolumab + trastuzumab + gimeracil/oteracil/tegafur Sensitive: C3 – Early Trials
ASCO-GI 2022 - 1 week
|
KRAS wild-type
|
Pancreatic Ductal Adenocarcinoma
|
KRAS wild-type
|
Pancreatic Ductal Adenocarcinoma
|
gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials
Cancer - 1 week
|
gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials
Cancer - 1 week
|
GOPC-ROS1 fusion + KRAS Q61H
|
CRC
|
GOPC-ROS1 fusion + KRAS Q61H
|
CRC
|
crizotinib Resistant: C4 – Case Studies
ASCO-GI 2022 - 1 week
|
crizotinib Resistant: C4 – Case Studies
ASCO-GI 2022 - 1 week
|
FGFR2 mutation
|
Gastric Cancer
|
FGFR2 mutation
|
Gastric Cancer
|
KIN-3248 Sensitive: D – Preclinical
ASCO-GI 2022 - 1 week
|
KIN-3248 Sensitive: D – Preclinical
ASCO-GI 2022 - 1 week
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
KIN-3248 Sensitive: D – Preclinical
ASCO-GI 2022 - 1 week
|
KIN-3248 Sensitive: D – Preclinical
ASCO-GI 2022 - 1 week
|
KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
RMC-6236 Sensitive: D – Preclinical
ASCO-GI 2022 - 1 week
|
RMC-6236 Sensitive: D – Preclinical
ASCO-GI 2022 - 1 week
|
MYC overexpression
|
Gastric Cancer
|
MYC overexpression
|
Gastric Cancer
|
WB100 Sensitive: D – Preclinical
Adv Sci (Weinh) - 1 week
|
WB100 Sensitive: D – Preclinical
Adv Sci (Weinh) - 1 week
|
MYC overexpression
|
Pancreatic Ductal Adenocarcinoma
|
MYC overexpression
|
Pancreatic Ductal Adenocarcinoma
|
WB100 Sensitive: D – Preclinical
Adv Sci (Weinh) - 1 week
|
WB100 Sensitive: D – Preclinical
Adv Sci (Weinh) - 1 week
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
ramucirumab Sensitive: B - Late Trials
Gastric Cancer - 2 weeks
|
ramucirumab Sensitive: B - Late Trials
Gastric Cancer - 2 weeks
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
ramucirumab Sensitive: B - Late Trials
Gastric Cancer - 2 weeks
|
ramucirumab Sensitive: B - Late Trials
Gastric Cancer - 2 weeks
|
HIF1A overexpression
|
CRC
|
HIF1A overexpression
|
CRC
|
5-fluorouracil Resistant: D – Preclinical
J Exp Clin Cancer Res - 2 weeks
|
5-fluorouracil Resistant: D – Preclinical
J Exp Clin Cancer Res - 2 weeks
|
HRAS mutation
|
CRC
|
HRAS mutation
|
CRC
|
bevacizumab Resistant: C3 – Early Trials
Br J Cancer - 3 weeks
|
bevacizumab Resistant: C3 – Early Trials
Br J Cancer - 3 weeks
|
CDH1 deletion
|
Gastric Cancer
|
CDH1 deletion
|
Gastric Cancer
|
vorinostat Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks
|
vorinostat Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks
|
CDH1 deletion
|
Gastric Cancer
|
CDH1 deletion
|
Gastric Cancer
|
MGCD0103 Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks
|
MGCD0103 Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks
|
CDH1 deletion
|
Gastric Cancer
|
CDH1 deletion
|
Gastric Cancer
|
SB939 Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks
|
SB939 Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks
|
CDH1 deletion
|
Gastric Cancer
|
CDH1 deletion
|
Gastric Cancer
|
SNDX-275 Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks
|
SNDX-275 Sensitive: D – Preclinical
Cancers (Basel) - 4 weeks
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Gastric Adenocarcinoma
|
No biomarker
|
Gastric Adenocarcinoma
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
|
BRCA2 mutation
|
Pancreatic Cancer
|
BRCA2 mutation
|
Pancreatic Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
pembrolizumab Sensitive: A1 - Approval
Merck (MSD) Press Release - 1 week
|
pembrolizumab Sensitive: A1 - Approval
Merck (MSD) Press Release - 1 week
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
BRCA1 mutation
|
Pancreatic Cancer
|
BRCA1 mutation
|
Pancreatic Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
infigratinib Sensitive: A1 - Approval
|
infigratinib Sensitive: A1 - Approval
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
infigratinib Sensitive: A1 - Approval
|
infigratinib Sensitive: A1 - Approval
|
IDH1 mutation
|
Cholangiocarcinoma
|
IDH1 mutation
|
Cholangiocarcinoma
|
ivosidenib Sensitive: A1 - Approval
|
ivosidenib Sensitive: A1 - Approval
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
|
nivolumab + ipilimumab Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
TPF Sensitive: A1 - Approval
|
TPF Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
TPF Sensitive: A1 - Approval
|
TPF Sensitive: A1 - Approval
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
pembrolizumab + trastuzumab Sensitive: A1 - Approval
|
pembrolizumab + trastuzumab Sensitive: A1 - Approval
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
|
cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
|
BRAF V600E
|
CRC
|
BRAF V600E
|
CRC
|
cetuximab + encorafenib Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
|
cetuximab + encorafenib Sensitive: A1 - Approval
ASCO-GI 2022 - 1 week
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
capecitabine Sensitive: A1 - Approval
|
capecitabine Sensitive: A1 - Approval
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
FOLFIRI Sensitive: A1 - Approval
|
FOLFIRI Sensitive: A1 - Approval
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
5-fluorouracil + irinotecan Sensitive: A1 - Approval
|
5-fluorouracil + irinotecan Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
HER-2 negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
HER-2 negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
HER-2 negative + PD-L1 expression
|
Gastric Cancer
|
HER-2 negative + PD-L1 expression
|
Gastric Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
Zirabev (bevacizumab biosimilar) Resistant: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Resistant: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
trifluridine/tipiracil Sensitive: A1 - Approval
|
trifluridine/tipiracil Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
trifluridine/tipiracil Sensitive: A1 - Approval
Gastric Cancer - 2 weeks
|
trifluridine/tipiracil Sensitive: A1 - Approval
Gastric Cancer - 2 weeks
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
trifluridine/tipiracil Sensitive: A1 - Approval
Gastric Cancer - 2 weeks
|
trifluridine/tipiracil Sensitive: A1 - Approval
Gastric Cancer - 2 weeks
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval
|
gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval
|
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
cabozantinib tablet Sensitive: A1 - Approval
|
cabozantinib tablet Sensitive: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
ziv-aflibercept IV Sensitive: A1 - Approval
|
ziv-aflibercept IV Sensitive: A1 - Approval
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
capecitabine Sensitive: A1 - Approval
|
capecitabine Sensitive: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
capecitabine Sensitive: A1 - Approval
|
capecitabine Sensitive: A1 - Approval
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
erlotinib Sensitive: A1 - Approval
|
erlotinib Sensitive: A1 - Approval
|
EGFR expression
|
CRC
|
EGFR expression
|
CRC
|
cetuximab Sensitive: A1 - Approval
|
cetuximab Sensitive: A1 - Approval
|
KRAS Q61
|
CRC
|
KRAS Q61
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
KRAS A146
|
CRC
|
KRAS A146
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
irinotecan Sensitive: A1 - Approval
|
irinotecan Sensitive: A1 - Approval
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
irinotecan Sensitive: A1 - Approval
|
irinotecan Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
|
sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Cancer
|
PD-L1 expression
|
Esophageal Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
AFP elevation
|
HCC
|
AFP elevation
|
HCC
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
regorafenib Sensitive: A1 - Approval
|
regorafenib Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
lenvatinib Sensitive: A1 - Approval
|
lenvatinib Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
sorafenib Sensitive: A1 - Approval
|
sorafenib Sensitive: A1 - Approval
|
KRAS G13
|
CRC
|
KRAS G13
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
KRAS G12
|
CRC
|
KRAS G12
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
HER-2 overexpression
|
Gastric Cancer
|
HER-2 overexpression
|
Gastric Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
regorafenib Sensitive: A1 - Approval
|
regorafenib Sensitive: A1 - Approval
|
KRAS K117
|
CRC
|
KRAS K117
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
KRAS A59
|
CRC
|
KRAS A59
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
KRAS G12S
|
CRC
|
KRAS G12S
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS Q61
|
CRC
|
NRAS Q61
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
NRAS Q61
|
CRC
|
NRAS Q61
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS G13
|
CRC
|
NRAS G13
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS G13
|
CRC
|
NRAS G13
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
NRAS G12
|
CRC
|
NRAS G12
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
NRAS G12
|
CRC
|
NRAS G12
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
NRAS A146
|
CRC
|
NRAS A146
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
